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Purpose/Objective: To estimate the number of cases of 
cancer that would benefit from radiotherapy (RT) by country, 
the survival and local control benefits of radiotherapy and to 
calculate projections of demand and benefit to 2035 for input 
to GTFRCC investment framework. 
Methods: The CCORE model of optimal utilisation of RT and 
Globocan data on cancer incidence and projections by 
country were used to calculate the number of cases with an 
indication for RT where RT was the treatment of choice. The 
estimate does not include non-melanomatous skin cancer or 
benign conditions. Survival and local control benefit were 
calculated by meta-analysis of available results for each 
radiotherapy indication for the 10 most common cancers that 
comprise 75% of the world cancer burden. Palliative benefit 
was not included.  
Results: In 2012 there were 14 million new cases of cancer in 
the world. 7 million (50%) would benefit from RT. More than 
half of the cases were in Low and Middle Income Countries. 
For the 10 most common cancers, 1.3 million cases would 
have a local control benefit and 0.5 million would have a 
survival benefit from RT if all patients were treated 
according to guidelines. By 2035, 12 million cases would have 
an indication for RT and the benefit for the 10 most common 
cancers would be local control for 2 million and improved 
survival for 0.8 million.  
Conclusion: In 2012 7 million cases of cancer require 
radiotherapy. This will increase to 12 million by 2035.  
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Purpose: To estimate the additional infrastructure required 
and the corresponding costs in terms of facilities, equipment 
and personnel to make up for the shortfall in current capacity 
and to provide uniform global access to radiation therapy by 
2035. 
Methods: An activities-based cost calculation model was 
implemented to generate: (1) an operating cost/fraction 
excluding building costs (Rate #1), and (2) a total 
cost/fraction including capital costs to establish 
new/increased capacity (Rate #2). For total cost estimations, 
the numbers of fractions needed were obtained from GTFRCC 
Work Group #1. For the rate determinations, a modified 
version of the IAEA cost calculator was used which included 
staffing level determinations based on an IAEA consultants’ 
group and confirmed with published data. Cost estimations 
were determined for four categories of gross national 
income. Input data included numbers of fractions required 
(from Work Group#1), typical components of a four-machine 
start-up department, 3-D conformal radiation therapy as the 
standard of care, and brachytherapy as needed. 
Commercially available, typical equipment costs were used. 
National salary information for professional staff and capital 
building costs were obtained through a Delphi questionnaire 
process along with confirmation from publicly available 
databases. To determine overall costs required for increasing 
capacity, existing resources were obtained from the IAEA 
DIRAC database along with information from additional 
independent sources. Sensitivity analysis was performed by 
controlled variations in the input parameters. Comparisons 
were also made to the published literature and the results of 
the ESTRO HERO project. The cost of training new 
professionals was also estimated. 
Results: The major cost drivers include capital costs of new 
facilities and equipment, and personnel salaries. The Delphi 
questionnaire results demonstrated a huge variation in 
salaries in different countries. As a result, the relative 
capital costs versus operating costs also had a large variation 
demonstrating a relative capital/operating ratio of about 70-
80%/20-30%  in high income countries compared to as much 
as the reverse in low income settings. Estimates for a 
particular operating model for Rate#1 and Rate#2 in low-to-
middle income settings are approximately US$50/fraction and 
US$300/fraction.  
Conclusion: The infrastructure and cost modeling provides a 
means of estimating the resources needed to advance 
radiation therapy capabilities in different settings around the 
world. One operating model indicates that, in low-to-middle 
income settings, about 2,000 new four-machine departments 
are required, corresponding to about 8,000 megavoltage 
machines along with 14,000, 8,300, and 35,000 radiation 
oncology, medical physics, and radiation therapy trainees, 
respectively.  
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Purpose: Radiotherapy (RT) is often thought to be a complex 
and expensive modality to implement in settings with limited 
resources and multiple competing priorities. We aimed to 
estimate the potential health and economic benefits that can 
be accrued in low- and middle-income countries (LMIC) with 
an increase in RT capacity over a 20-year period from 2015 to 
2035. 
Methods: We developed a series of Markov decision-analytic 
models for 9 cancer sites (breast, cervix, colorectal, head 
and neck, haematologic, lung, esophagus, prostate, stomach) 
to simulate the total life years saved (LYs), incremental 
costs, and selected economic benefits accrued from scaling 
up RT capacity at 3 different rates of investment (gradual, 
rapid, aspirational). Capacity was estimated from RT demand 
data (from Working Group #1) and the IAEA Directory of 
Radiotherapy Services (DIRAC). Analyses were stratified by 
World Bank income group region and outcome measures were 
evaluated under scenarios of existing and expanded 
radiotherapy capacity, with results projected over 20 years. 
The total operational and infrastructure costs (from Working 
Group #2) associated with RT scale were compared with the 
projected economic gains, defined as improved labour 
productivity measured using gross domestic product (GDP). 
All future costs and health benefits were discounted at an 
